High-Throughput Proteomics Identifies THEMIS2 As Biomarker of Inferior Treatment-Free Survival in Chronic Lymphocytic Leukemia
Paul J. Hengeveld(Erasmus MC), Mark‐David Levin(Albert Schweitzer Ziekenhuis), Lina van der Straten(Erasmus MC), Peter E. Westerweel(Cornell University), Henk‐Jan Boiten(Erasmus MC), Melissa Rijken(Erasmus MC Cancer Institute), Kirsten J. Gussinklo(Erasmus MC Cancer Institute), Arnon P. Kater(Sanford Burnham Prebys Medical Discovery Institute), P. Martijn Kolijn(Erasmus MC), Jeroen Demmers(Erasmus MC), Peter J.M. Valk(Erasmus MC), Anton W. Langerak(Erasmus MC), Wouter Doff(Erasmus MC), Jorn L. J. C. Assmann(Erasmus MC), Julie Dubois(Amsterdam University Medical Centers)
Cited by 0
Related Papers
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
|Cancer Cell|2010|2.7k
Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC
|Nature|2013|2.1k
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2018|907